BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

First German Patient Enrolled Pushes Rox Medical Inc. Past Halfway Point in CONTROL-HTN trial


8/20/2013 9:35:21 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN CLEMENTE, Calif., Aug. 19, 2013 /PRNewswire/ -- ROX Medical has crossed the halfway point in the CONTROL-HTN international, multi centre, randomized controlled hypertension trial. The milestone was met with the enrollment of the first patient from Prof. Markus van der Giet and Prof. Walter Zidek of the Charite Hospital, Benjamin Franklin Campus, Berlin. The CONTROL-HTN trial is evaluating the ROX FLOW procedure - creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension.

(Logo: http://photos.prnewswire.com/prnh/20130304/LA70984LOGO)

ROX Medical's FLOW procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system.

"We have been thrilled by the enthusiasm of the clinical centers in the CONTROL-HTN trial and congratulate the Berlin physicians on the first enrollment in Germany," commented ROX CEO Rodney Brenneman.

The ROX FLOW procedure for hypertension is not approved for use in the U.S.

SOURCE ROX Medical



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES